GlassScriptPhysician profile
Adam G Burroughs
NPI 1134488281
$2,085.25
in general payments reported to CMS, 2019-2025
20 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $210 · 2021: $56.87 · 2022: $542 · 2023: $556 · 2024: $306 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $728.93 | 2020-2025 | Lifevest |
| Pfizer INC. | $185.55 | 2022-2024 | |
| Ge Healthcare | $173.71 | 2020 | |
| Inari Medical, INC. | $164.12 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Surmodics, INC. | $132.05 | 2023-2025 | Pounce Venous Thrombectomy System, Pounce Thrombectomy, Pounce Thrombectomy System |
| Actelion Pharmaceuticals US, INC. | $101.62 | 2022-2023 | Opsumit |
| Abbott Laboratories | $85.08 | 2021-2025 | Cardiomems, Mitraclip |
| Abiomed | $73.22 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.04 | 2023-2025 | Camzyos, Eliquis |
| Stryker Corporation | $59.47 | 2025 | Clottriever Bold Catheter, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $57.48 | 2022-2024 | |
| Novo Nordisk INC | $48.40 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $48.25 | 2022 | |
| Amgen INC. | $39.93 | 2023-2024 | Repatha |
| Kestra Medical Technology Services, INC. | $34.04 | 2024 | Assure Wcd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $25.04 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $20.56 | 2024 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.09 | 2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $15.39 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.28 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.